@article{2999603,
    title = "The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria",
    author = "Zuberbier, T. and Abdul Latiff, A.H. and Abuzakouk, M. and Aquilina, S. and Asero, R. and Baker, D. and Ballmer-Weber, B. and Bangert, C. and Ben-Shoshan, M. and Bernstein, J.A. and Bindslev-Jensen, C. and Brockow, K. and Brzoza, Z. and Chong Neto, H.J. and Church, M.K. and Criado, P.R. and Danilycheva, I.V. and Dressler, C. and Ensina, L.F. and Fonacier, L. and Gaskins, M. and Gáspár, K. and Gelincik, A. and Giménez-Arnau, A. and Godse, K. and Gonçalo, M. and Grattan, C. and Grosber, M. and Hamelmann, E. and Hébert, J. and Hide, M. and Kaplan, A. and Kapp, A. and Kessel, A. and Kocatürk, E. and Kulthanan, K. and Larenas-Linnemann, D. and Lauerma, A. and Leslie, T.A. and Magerl, M. and Makris, M. and Meshkova, R.Y. and Metz, M. and Micallef, D. and Mortz, C.G. and Nast, A. and Oude-Elberink, H. and Pawankar, R. and Pigatto, P.D. and Ratti Sisa, H. and Rojo Gutiérrez, M.I. and Saini, S.S. and Schmid-Grendelmeier, P. and Sekerel, B.E. and Siebenhaar, F. and Siiskonen, H. and Soria, A. and Staubach-Renz, P. and Stingeni, L. and Sussman, G. and Szegedi, A. and Thomsen, S.F. and Vadasz, Z. and Vestergaard, C. and Wedi, B. and Zhao, Z. and Maurer, M.",
    journal = "Allergy: European Journal of Allergy and Clinical Immunology",
    year = "2022",
    volume = "77",
    number = "3",
    pages = "734-766",
    publisher = "John Wiley and Sons Inc",
    doi = "10.1111/all.15090",
    keywords = "autoantibody;  cyclosporine;  dermatological agent;  histamine H1 receptor antagonist;  omalizumab, Article;  child;  chronic urticaria;  comorbidity;  consensus development;  diagnostic procedure;  differential diagnosis;  disease activity;  disease assessment;  disease burden;  disease classification;  disease control;  disease course;  disease duration;  food;  health care access;  human;  infection;  inflammation;  lactation;  lifetime prevalence;  mast cell;  nonhuman;  palliative therapy;  pathophysiology;  physiological stress;  practice guideline;  pregnant woman;  quality of life;  urticaria",
    abstract = "This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria. © 2021 GA²LEN. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd."
}